1. Kuiper JJ, de Man RA, van Buuren HR. Review article: Management of ascites and associated complications in patients with cirrhosis. Aliment Pharmacol Ther 2007;26(Suppl 2):183-193. 18081661.
2. Kuiper JJ, van Buuren HR, de Man RA. Ascites in cirrhosis: a review of management and complications. Neth J Med 2007;65:283-288. 17890787.
3. Hou W, Sanyal AJ. Ascites: diagnosis and management. Med Clin North Am 2009;93:801-817. vii. 19577115.
4. Runyon BA. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. Hepatology 2013;57:1651-1653. 23463403.
5. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53:397-417. 20633946.
6. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009;49:2087-2107. 19475696.
9. Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997;113:579-586. 9247479.
10. Alessandria C, Elia C, Mezzabotta L, Risso A, Andrealli A, Spandre M, et al. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study. Dig Liver Dis 2011;43:881-886. 21741331.
11. Alsebaey A, Abdel-Razek W, Bassuni A, Rewisha E, Khalil M, Waked I. Prevention of paracentesis-induced circulatory dysfunction: could we use other albumin alternatives? Egyptian Liver J 2013;3:118-125.
13. Singh V, Kumar R, Nain CK, Singh B, Sharma AK. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study. J Gastroenterol Hepatol 2006;21:303-307. 16460491.
14. Lata J, Marecek Z, Fejfar T, Zdenek P, Brůha R, Safka V, et al. The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites--a randomized multicentric study. Hepatogastroenterology 2007;54:1930-1933. 18251131.
15. Abdullah MH, Saleh SM, Morad WS. Terlipressin versus norepinephrine to counteract intraoperative paracentesis induced refractory hypotension in cirrhotic patients. Egyptian J Anaesthesia 2012;1:29-35.
16. Singh V, Kumar B, Nain CK, Singh B, Sharma N, Bhalla A, et al. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized pilot study. J Intern Med 2006;260:62-68. 16789980.
17. Singh V, Dheerendra PC, Singh B, Nain CK, Chawla D, Sharma N, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2008;103:1399-1405. 18547224.
18. Appenrodt B, Wolf A, Grünhage F, Trebicka J, Schepke M, Rabe C, et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int 2008;28:1019-1025. 18410283.
19. Hamdy H, ElBaz AA, Hassan A, Hassanin O. Comparison of midodrine and albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients: a randomized pilot study. J Clin Gastroenterol 2014;48:184-188. 23842215.
20. Planas R, Ginès P, Arroyo V, Llach J, Panés J, Vargas V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology 1990;99:1736-1744. 1699835.
21. Ginès A, Fernández-Esparrach G, Monescillo A, Vila C, Domènech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996;111:1002-1010. 8831595.
22. García-Compean D, Blanc P, Larrey D, Daures JP, Hirtz J, Mendoza E, et al. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: a randomized controlled trial. Ann Hepatol 2002;1:29-35. 15114293.
23. Moreau R, Valla DC, Durand-Zaleski I, Bronowicki JP, Durand F, Chaput JC, et al. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int 2006;26:46-54. 16420509.
24. El-Ashry N, El-Damarawy M, Salem M, Mogawer S. Large volume abdominal paracentesis effect on some humoral factors and cardiac performance in patients with liver cirrhosis and tense ascities. J Egypt Soc Parasitol 2007;37:571-584. 17985589.
25. Abdel-Khalek EE, Arif SE. Ran{Runyon, 2009 #66}{Runyon, 2009 #66}{Runyon, 2009 #66}domized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab J Gastroenterol 2010;11:24-29.
27. Cabrera J, Inglada L, Quintero E, Jimenez W, Losada A, Mayor J, et al. Large-volume paracentesis and intravenous saline: effects on the renin-angiotensin system. Hepatology 1991;14:1025-1028. 1959849.
28. Sola-Vera J, Miñana J, Ricart E, Planella M, González B, Torras X, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147-1153. 12717396.
29. Sersté T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017-1022. 20583214.
30. Sersté T, Francoz C, Durand F, Rautou PE, Melot C, Valla D, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol 2011;55:794-799. 21354230.
32. Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000;32:142-153. 10673079.
33. McGibbon A, Chen GI, Peltekian KM, van Zanten SV. An evidence-based manual for abdominal paracentesis. Dig Dis Sci 2007;52:3307-3315. 17393312.
35. Coll S, Vila MC, Molina L, Gimenez MD, Guarner C, Solà R. Mechanisms of early decrease in systemic vascular resistance after total paracentesis: influence of flow rate of ascites extraction. Eur J Gastroenterol Hepatol 2004;16:347-353. 15195901.
36. Carl DE, Ghosh S, Cheng J, Gehr TW, Stravitz RT, Sanyal A. Post-paracentesis circulatory derangements are related to monocyte activation. Liver Int 2014;34:1001-1007. 24373155.
37. Johnson KB, Mueller JL, Simon TG, Zheng H, King LY, Makar RS, et al. Reduced Albumin Dosing During Large-Volume Paracentesis Is Not Associated with Adverse Clinical Outcomes. Dig Dis Sci 2015;60:2190-2195. 25724164.